Sapient Capital LLC Purchases 3,404 Shares of AbbVie Inc. (NYSE:ABBV)

Sapient Capital LLC grew its position in AbbVie Inc. (NYSE:ABBV) by 1.3% during the fourth quarter, HoldingsChannel.com reports. The firm owned 258,899 shares of the company’s stock after buying an additional 3,404 shares during the quarter. AbbVie accounts for approximately 0.9% of Sapient Capital LLC’s investment portfolio, making the stock its 22nd biggest holding. Sapient Capital LLC’s holdings in AbbVie were worth $46,006,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. RPg Family Wealth Advisory LLC bought a new stake in AbbVie in the 3rd quarter valued at approximately $28,000. Fiduciary Advisors Inc. bought a new stake in shares of AbbVie in the fourth quarter worth $29,000. Retirement Wealth Solutions LLC acquired a new position in AbbVie during the fourth quarter worth $35,000. Mizuho Securities Co. Ltd. grew its position in AbbVie by 100.0% in the third quarter. Mizuho Securities Co. Ltd. now owns 200 shares of the company’s stock valued at $39,000 after purchasing an additional 100 shares in the last quarter. Finally, MidAtlantic Capital Management Inc. acquired a new stake in AbbVie in the 3rd quarter valued at $39,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Raymond James restated an “outperform” rating and set a $220.00 price objective (up from $218.00) on shares of AbbVie in a research note on Monday, February 3rd. Argus upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Monday, November 4th. Wolfe Research began coverage on AbbVie in a research note on Friday, November 15th. They set an “outperform” rating and a $205.00 price objective on the stock. Truist Financial boosted their target price on shares of AbbVie from $211.00 to $217.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Finally, BMO Capital Markets increased their price target on shares of AbbVie from $208.00 to $215.00 and gave the company an “outperform” rating in a research note on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $208.35.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $190.31 on Tuesday. AbbVie Inc. has a one year low of $153.58 and a one year high of $207.32. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. The firm has a market cap of $336.30 billion, a price-to-earnings ratio of 79.29, a P/E/G ratio of 1.53 and a beta of 0.58. The stock’s fifty day moving average price is $177.54 and its two-hundred day moving average price is $185.75.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same quarter in the prior year, the business earned $2.79 EPS. On average, equities analysts forecast that AbbVie Inc. will post 12.32 EPS for the current year.

Insider Activity

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the transaction, the senior vice president now owns 6,983 shares in the company, valued at approximately $1,202,751.92. This trade represents a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.25% of the stock is owned by company insiders.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.